How big is the GI Stool Testing Market?

The GI Stool Testing Market size is expected to reach USD 507.52 million in 2024 and grow at a CAGR of 6.54% to reach USD 696.67 million by 2029. Read More

What is the current GI Stool Testing Market size?

In 2024, the GI Stool Testing Market size is expected to reach USD 507.52 million. Read More

Who are the key players in GI Stool Testing Market?

Abbott Laboratories, Genova Diagnostics, bioMérieux SA, Cardinal Health and Danaher Corporation (Beckman Coulter, Inc.) are the major companies operating in the GI Stool Testing Market. Read More

Which is the fastest growing region in GI Stool Testing Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in GI Stool Testing Market?

In 2024, the North America accounts for the largest market share in GI Stool Testing Market. Read More

What years does this GI Stool Testing Market cover, and what was the market size in 2023?

In 2023, the GI Stool Testing Market size was estimated at USD 474.33 million. The report covers the GI Stool Testing Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the GI Stool Testing Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

GI Stool Testing Market Share

Statistics for the 2023 & 2024 GI Stool Testing market share, created by Mordor Intelligence™ Industry Reports. GI Stool Testing share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of GI Stool Testing Industry

The GI stool testing market is fragmented in nature, with the presence of major players in the market. Collaborations, mergers, and acquisitions by companies related to GI stool testing are expected to boost market growth. Some of the companies which are currently dominating the GI stool testing market are bioMérieux SA, DiaSorin SpA, Cenegenics Corporation, Abbott Laboratories, Epitope Diagnostics Inc., Genova Diagnostics, Danaher Corporation (Beckman Coulter Inc.), ScheBo Biotech AG, CTKBiotech Inc. Inc., and Cardinal Health.